Catyalyst (CPRX) Slammed as CPP-109 Missed Primary Endpoint in Phase IIb
Tweet Send to a Friend
Catyalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) shares are getting slammed Thursday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


